Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.7901
+0.0401 (5.35%)
At close: Apr 2, 2025, 4:00 PM
0.7721
-0.0180 (-2.28%)
After-hours: Apr 2, 2025, 5:31 PM EDT
Cue Biopharma Revenue
In the year 2024, Cue Biopharma had annual revenue of $9.29M with 69.16% growth. Cue Biopharma had revenue of $1.58M in the quarter ending December 31, 2024, a decrease of -13.45%.
Revenue (ttm)
$9.29M
Revenue Growth
+69.16%
P/S Ratio
4.55
Revenue / Employee
$175,226
Employees
53
Market Cap
50.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CUE News
- 2 days ago - Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Cue Biopharma Announces Strategic Organizational Transition - GlobeNewsWire
- 5 months ago - Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting - GlobeNewsWire
- 6 months ago - Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 6 months ago - Cue Biopharma Announces Pricing of $12.0 Million Public Offering - GlobeNewsWire